Business Context and Reporting Period
This Form 8-K Current Report is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on May 4, 2016, regarding events occurring on May 2 and May 3, 2016. The filing discloses the entry into a Material Definitive Agreement for an underwritten public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 20,000,000 shares of Common Stock and 20,000,000 Warrants.
- Public Offering Price: $0.40 per unit (one share and one warrant).
- Underwriter Purchase Price: $0.376 per unit (representing a 6.0% discount).
- Gross Proceeds: Expected to be $8,000,000.
- Net Proceeds: Approximately $7,420,000 (after underwriting discounts, commissions, and estimated expenses, assuming no warrant exercise).
- Warrant Terms: Initial exercise price of $0.40; exercisable immediately; 5-year expiration (expected May 6, 2021); not listed on any exchange.
- Underwriters: Roth Capital Partners, LLC (sole book-runner) and Brean Capital (co-manager).
Material Changes and Transaction Terms
The primary material change is the dilution of existing shareholders due to the issuance of 20,000,000 new shares and the creation of 20,000,000 warrants. The filing details specific warrant provisions:
- Adjustments: Exercise price subject to adjustment for corporate events (splits, dividends) and subsequent sales of stock below the exercise price.
- Extraordinary Transactions: In the event of a merger or asset sale, holders may elect cash payment based on the Black-Scholes model value of the warrant.
- Beneficial Ownership Limitation: Warrants cannot be exercised if the holder would own more than 4.99% of outstanding shares (electable increase to 9.99% with notice).
- Cashless Exercise: If the registration statement for underlying shares is ineffective, warrants may be exercised on a cashless basis.
Outlook, Risks, and Management Commentary
Management expects the securities to be issued and delivered on or about May 6, 2016, subject to customary closing conditions. The filing includes forward-looking statements regarding the anticipated closing and net proceeds.
- Risks: The Company may fail to satisfy closing conditions on a timely basis or at all.
- Regulatory Status: The offering is made pursuant to a Registration Statement on Form S-3 declared effective on June 19, 2014. A final prospectus supplement was filed on May 4, 2016.
- Legal Disclaimer: Representations in the Underwriting Agreement are made solely for the benefit of the parties to that agreement and are qualified by confidential disclosures.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received (expected ~$7.42 million).
- Confirm the effective date of the final prospectus supplement filed on May 4, 2016.
- Review the full text of the Underwriting Agreement (Exhibit 1.01) for specific covenants and conditions precedent.
- Monitor the Company's ability to maintain the registration statement effectiveness for warrant exercises.
- Check for any subsequent filings regarding the exercise of warrants or changes in the beneficial ownership limitation.